23andMe (NASDAQ:ME) mentioned in an SEC submitting that it plans to put off about 9% of its workforce, or round 75 staff, as a part of an organization restructuring.
The genetics-focused healthcare firm mentioned it expects the cuts to be made principally throughout Q1 of the corporate’s fiscal yr ending March 31, 2024. The corporate expects to incur expenses of roughly $3.5M from the transfer, most of which can be acknowledged in Q1 of fiscal 2024.
23andMe mentioned the cuts ought to end in financial savings of roughly $12.8M in payroll and advantages bills.
Extra on 23andMe:
23 and Me fiscal 2024 income outlook misses consensus
Greenlight Capital provides NY Neighborhood Bancorp; exits Victoria’s Secret, 23andMe